Showing posts with the label
BioNTech
IndustryPRwire - Pfizer and BioNTech SE announced they will supply an additional 100 million doses of COMIRNATY®, the companies’ COVID-19 Vaccine, to the 27 European Union (EU) member states in 202…
IndustryPRwire — Pfizer and BioNTech SE announced a second agreement with the U.S. government to supply an additional 100 million doses of the companies’ COVID-19 vaccine from production facilities i…
IndustryPRwire - Pfizer and BioNTech SE announced that the European Commission (EC) has granted a conditional marketing authorization (CMA) to Pfizer and BioNTech for COMIRNATY® (also known as BNT162…
IndustryPRwire — BioNTech SE and Shanghai Fosun Pharmaceutical announced an agreement to supply Mainland China with an initial 100 million doses of their BNT162 mRNA-based vaccine candidate against C…
IndustryPRwire — Pfizer and BioNTech SE announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted (17 to 4) in support …
IndustryPRwire — Pfizer Canada and BioNTech SE announced that Health Canada has granted Authorization under Interim Order for the emergency use of their mRNA COVID-19 vaccine (BNT162b2). The distri…
IndustryPRwire -- Pfizer and BioNTech SE announced that the Medicines & Healthcare Products Regulatory Agency (MHRA) in the U.K. has granted a temporary authorization for emergency use for their…
IndustryPRwire — Pfizer and BioNTech SE have submitted on Monday, November 30, 2020, a formal Application for Conditional Marketing Authorization (CMA) to the European Medicines Agency (EMA) for the…
IndustryPRwire – BioNTech SE and Shanghai Fosun Pharmaceutical jointly announced that their lead mRNA COVID-19 vaccine candidate BNT162b2 will be evaluated in a Phase 2 clinical trial in Taizhou an…
IndustryPRwire -- BioNTech SE and InstaDeep Ltd today announced a multi-year strategic collaboration aimed at applying the latest advances in artificial intelligence (AI) and machine learning (ML) te…
Pfizer and BioNTech announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against …
Pfizer and BioNTech announced that they have reached an agreement with the European Commission to supply 200 million doses of their investigational BNT162b2 mRNA-based vaccine candidate against COVI…
Pfizer and BioNTech announced their mRNA-based vaccine candidate, BNT162b2, against SARS-CoV-2 has demonstrated evidence of efficacy against COVID-19 in participants without prior evidence of SARS-C…
Pfizer Canada and BioNTech SE announced the initiation of a rolling submission to Health Canada for BNT162b2, the lead candidate from the companies’ vaccine development program against COVID-19. The …
Pfizer and BioNTech today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine development program agai…
